// App-Quantinova.ai

: Phase I Study of Palbociclib Alone and in Combination in Patients with Relapsed and Refractory (R/R) Leukemias

Researchers

Presenter

  • Tapan M. Kadia

Principal Investigators

  • Marina Y. Konopleva

  • Guillermo Garcia-Manero

  • Christopher B. Benton

  • William G. Wierda

  • Prithviraj Bose

  • Musa E. Yilmaz

  • Elias J. Jabbour

  • Steven M. Kornblau

  • Kapil N. Bhalla

  • Naveen Pemmaraju

  • Nitin Jain

  • Rashmi Malla

  • Gautam Borthakur

  • Jorge E. Cortes

  • Farhad Ravandi

  • Hagop M. Kantarjian

Medical Centers

  • Department of Radiology, MD Anderson Cancer Center, Houston, TX

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Department of Radiology, MD Anderson Cancer Center, Houston, TX

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Blood/haematological Diseases

Disease

  • Acute lymphoblastic leukemia

  • Acute myelocytic leukemia

  • Acute Leukemia

  • T-cell acute lymphoblastic leukemia

  • B-cell acute lymphoblastic leukemia

Biomarkers

  • Cyclin dependent kinase 6

  • Cyclin Dependent Kinase Inhibitor 2A

  • Fms related tyrosine kinase 3

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Palbociclib

  • Decitabine

  • Sorafenib

  • Hydroxycarbamide

Outcome

  • N/A

Study Design

  • Pharmacodynamics

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved